CLAIMS

1. Use of at least one substrate of organic anion transporting polypeptide 1B1 (OATP1B1), breast cancer resistance protein (BCRP), or P-glycoprotein (P-gp) and compound 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of chronic graft-versus-host-disease (cGVHD) in a subject, wherein the dose of the at least one substrate of OATP1B1, BCRP, or P-gp is to be reduced as compared to the clinically-recommended dose when the substrate is for administration without the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof .

2. The use according to claim 1, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof comprises the mesylate salt of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide.

3. The use according to claim 1 or claim 2, wherein the dose of the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof is equivalent to a dose of about 200 mg of the free base.

4. The use according to any one of claims 1 to 3, wherein the medicament comprises a substrate of OATP1B1.

5. The use according to claim 4, wherein the substrate of OATP1B1 is at least one of estradiol-17β-glucuronide, pitavastatin, pravastatin, rosuvastatin, atorvastatin, lovastatin, or simvastatin.

6. The use according to any one of claims 1 to 3, wherein the medicament comprises a substrate of BCRP.

7. The use according to claim 6, wherein:
(a) the substrate of BCRP is rosuvastatin, or

(b) the substrate of BCRP is rosuvastatin at a dose that does not exceed 5 mg daily.

8. The use according to any one of claims 1 to 3, wherein the medicament comprises a substrate of P-gp.

9. The used according to claim 8, wherein:
(a) the substrate of P-gp is dabigatran etexilate; or
(b) the substrate of P-gp is dabigatran etexilate at a dose that is less than about 300 mg.

10. The use according to claim 1, wherein the dose of the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof is equivalent to a dose of about 200 mg of the free base, and wherein the dose of the at least one substrate of OATP1B1, BRCP, or P-gp is to be reduced by about half as compared to the clinically-recommended dose when the substrate is for administration without the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof .

11. The use according to claim 10, wherein the at least one substrate of OATP1B1, BCRP, or P-gp is rosuvastatin.

12. The use according to claim 10 or claim 11, wherein the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof comprises the mesylate salt of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide.

13. The use according to any one of claims 1 to 12, wherein the subject has cGVHD and has failed at least two prior lines of systemic therapy for the cGVHD.

14. Use of at least one substrate of organic anion transporting polypeptide 1B1 (OATP1B1), breast cancer resistance protein (BCRP), or P-glycoprotein (P-gp) and compound 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof in the manufacture of a

medicament for the treatment of chronic graft-versus-host-disease (cGVHD) in a subject, wherein the medicament to be administered to the subject comprises the steps of:

(a) the subject is to be determined whether is in need of a medicament comprising at least one substrate of OATP1B1, BCRP, or P-gp;

(b) the subject is to be determined the clinically-recommended dose of the at least one substrate of OATP1B1, BCRP, or P-gp when the substrate is for administration without the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or a pharmaceutically acceptable salt thereof;

(c) the subject is to be determined a lower dose of the at least one substrate of OATP1B1, BCRP, or P-gp to mediate the increase in exposure of the substrate due to the administration of the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof; and

(d) the medicament comprising at least one substrate of OATP1B1, BCRP, or P-gp and the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof is to be administered to the subject.

15. The use according to claim 14, wherein:

(a) the 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide or pharmaceutically acceptable salt thereof comprises the mesylate salt of 2-{3-[4-(1*H*-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-*N*-(propan-2-yl) acetamide; or

(b) the at least one substrate of OATP1B1, BCRP, or P-gp is rosuvastatin.